Lupin Limited has announced the grant of 6,495 stock options to its employees under the company's established employee stock option plan. The grant was approved by the Nomination and Remuneration Committee on April 09, 2026, and disclosed to stock exchanges in compliance with regulatory requirements.

Stock Option Grant Details

The pharmaceutical company granted the options under its existing Lupin Employees Stock Option Plan 2011. All 6,495 options were allocated under this single plan structure.

Vesting and Exercise Terms

Each stock option entitles the grantee to subscribe to one equity share of the company valued at ₹2.00 upon successful vesting. The company has structured the vesting schedule to promote employee retention and long-term commitment.

The vesting schedule follows a systematic approach:

• 25% of options vest after completion of one year from grant date
• 25% vest after completion of two years
• 25% vest after completion of three years
• 25% vest after completion of four years

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was communicated to both the National Stock Exchange of India Limited and BSE Limited through official channels.

The grant represents part of Lupin's ongoing employee incentive strategy, designed to align employee interests with shareholder value creation through equity participation in the company's growth.

Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the US Food and Drug Administration for Dapagliflozin Tablets in 5mg and 10mg strengths. The regulatory milestone marks a significant addition to the company's diabetes treatment portfolio.

FDA Approval Details

The approved Dapagliflozin Tablets are indicated for treating adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Additionally, the medication is approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors.

Strategic Portfolio Enhancement

This FDA approval significantly strengthens Biocon's expanding diabetes portfolio, which spans multiple therapeutic approaches including oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides. The comprehensive portfolio demonstrates the company's integrated approach to addressing the evolving needs of people living with diabetes globally.

Manufacturing Standards

Dapagliflozin Tablets will be manufactured at Biocon's FDA-approved facilities, ensuring compliance with global quality and regulatory standards. The company's established manufacturing infrastructure supports its ability to deliver high-quality pharmaceutical products to international markets.

Regulatory Communication

Biocon Limited formally notified stock exchanges BSE Limited and National Stock Exchange of India Limited about this development through its subsidiary Biocon Pharma Limited. The announcement was made in compliance with regulatory requirements for material developments.